comprehensive -WSS

comprehensive

author：hotspot 2025-09-02 13:43:48 - browse：8

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： STAT wants to know your pick for a great summer read or listen

Wikipedia

WSS

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Medicare Advantage's lean provider networks lead CMS complaints

Senators tussle over abortion against the backdrop of a presidential campaign

Vertex Pharmaceuticals may move headquarters in Boston

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Anthony Fauci pushes back on GOP claims during Covid hearing

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

Donor acceptance rates hint at racial, gender bias in heart transplants: study

The cancer drug shortage isn’t new — and neither are the solutions

ASCO Daily Recap: CAR

Sports medicine is finally prioritizing gender equality

Stopping antidepressants leads to symptoms for 1 in 6 patients

DIEP, the 'gold standard' of breast reconstruction, is under threat

Fight over Supreme Court dialysis ruling puts kidney patients at risk

New air purifier tech could be key to improving indoor air quality

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

entertainment

Roche subsidiary Foundation Medicine opens new headquarters

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Food as medicine: Medically tailored meals may get standardized

Illumina board agrees to spin off Grail, as divestment plans proceed

Merck drug for rare lung condition set for approval in U.S.

FDA approves Moderna’s RSV vaccine, its second licensed product

Wikipedia

explore

focus

Wikipedia